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Abstract
Background: The positive effects of statin therapy in acute coronary syndromes (ACS) may
result from their anti-inflammatory and anti-thrombotic effects. The aim of the study was to
compare the influence of standard and high-dose statin therapies in ACS on the serum mark-
ers of immune and platelet activation.
Material and methods: We examined 44 patients with ACS randomised into two groups:
Group S(+) — 22 patients with ACS who were administered high doses of simvastatin (80mg
per day) over a period of one month from a cardiac event; Group S(–) — 22 patients with ACS
treated by standard doses of statins. In all patients successful percutaneous coronary interven-
tions (PCI) were performed. Laboratory analyses were performed at the baseline on the 7th and
30th days from an ACS and involved the following: platelet-derived growth factor (PDGF),
tumour necrosis factor (TNF) alpha, soluble forms of TNF receptor (sTNFR 1 and 2),
Interleukin-2 (IL-2), and IL-10.
Results: During a one-month follow-up we found no difference between clinical data and the
baseline levels of the assessed markers in the groups examined. There were no differences in
the consecutive measurements of TNF-a, sTNFR1, sTNFR 2, IL-2, and IL-10 levels. Serum
concentrations of PDGF were significantly lower on the 7th and 30th days in group S(+)
(7th: 6111 ± 1834 pg/ml, p = 0.037; 30th: 5735 ± 1089 pg/ml, p = 0.016, respectively) in
comparison to group S(–) (7th: 7292 ± 1952 pg/ml; 30th: 7034 ± 2008 pg/ml, respectively).
Conclusions: High doses of simvastatin administered over a period of one month following an
acute coronary syndrome were associated with  a  significant decrease in serum PDGF levels
without influence on the activation of serum immune markers. (Folia Cardiol. 2006; 13: 326–330)
platelet-derived growth hormone, cytokines, acute coronary syndrome
Introduction
The question of high-dose statin administration
in acute coronary syndromes (ACS) has been raised
in the literature for several years. Analysis of clini-
cal trials (MIRACL, PROVE-IT) suggests that the
primary therapeutic objective is a reduction in the
risk of cardiovascular incidents [1–3] and not solely
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the normalisation of lipid markers. The early use
of these medicines would seem, therefore, to be
highly recommended, regardless of the initial se-
rum lipid concentration.
Other than the lipid-related mechanisms, the
beneficial effects of statins in ACS have not been
fully explored. There are considerable data hinting
at the influence of statins on the inflammatory pro-
cesses, believed to be involved in the early stage
of atherosclerosis development and its consequen-
ces [4]. Not only its early administration but also
the dose administered seems to be of great signifi-
cance [4]. Our observation suggests that the high-
dose statins administered in ACS improve the en-
dothelium function in the follow-up [7]. In this ar-
ticle we attempt to determine whether the
high-dose statins, administered over a period of one
month following an ACS, influence the immunolo-
gical activation.
Material and methods
A total of 44 consecutive patients who had been
diagnosed with an acute coronary syndrome were
included in the study. The study group comprised
12 patients with unstable angina (Braunwald’s III
B class) and 32 patients with an acute myocardial
infarction. In all subjects urgent successful percu-
taneous coronary interventions (PCI) were perfor-
med. They were hospitalised in the Cardiology
Department of the Silesian University School of
Medicine between June and October 2003.
The patients were randomised into two groups:
— group S(+) — 22 patients with ACS to whom
high doses of simvastatin were administered
(80 mg per day) over a period of one month
from the cardiac event;
— group S(–) — 22 patients with ACS treated by
standard doses of statins (previous statin the-
rapy was continued without serum lipids ana-
lysis at a mean of 20 mg simvastatin per day,
or 20 mg simvastatin were administered). The
statin had been administered to 10 patients
before hospital admission.
The exclusion criteria included: 1) previous my-
ocardial infarction within the preceding six months;
2) infectious diseases and malignant diseases confir-
med by clinical, laboratory analyses and, in some ca-
ses, by specialist consultations; 3) ECG abnormalities
that would hamper ST-T segment analysis.
The clinical characteristics of the patients were
drawn up on the basis of the following:
— the medical history of the patients with special
attention drawn to smoking status (whether
they were non-smokers, ex-smokers or cur-
rent smokers) and to concomitant diseases
(such as hypertension and diabetes mellitus);
— results of physical examination;
— laboratory analyses: serum lipids (total chole-
sterol, HDL-cholesterol, LDL-cholesterol, tri-
glycerides), serum immune marker concentra-
tions: platelet-derived growth factor (PDGF),
tumour necrosis factor alpha (TNF-a), soluble
TNF receptor 1 and 2 (sTNFR 1 and 2), Inter-
leukin 2 (IL-2), IL-10;
— ECG — diagnostic criterion;
— echocardiography — left ventricular ejection
fraction (LVEF), wall motion score index
(WSMI), left ventricular mass (LVM) and left
vetricular mass index (LVMI) were all assessed;
— coronary angiography — a division into one,
two and three-vessel disease was used.
The complex assessment of the study group
was performed at the baseline on the 7th and 30th
days from the ACS.
The study was approved by the local ethics
committee. All subjects gave their informed con-
sent to the study.
Statistical analysis
All statistical analyses were carried out using
Excel v. 2000 Microsoft Company. The results are
expressed as mean ± SEM and some data as me-
dian values. Student’s t-test was used for normally
distributed continuous variables. In the case of ab-
normal distribution the Mann-Whitney test was
used. Discontinuous variables were tested by a con-
tingency c2 with the Yates correction. P < 0.05 was
considered statistically significant.
Results
We included 44 patients with ACS: 12 patients
with unstable angina (mean age: 51.8 ± 8.5 years;
angina symptom history: 2 days – 16 years) and
32 patients who had been diagnosed with AMI
(mean age: 51.7 ± 10.6 years; angina symptom hi-
story: 2 h – 11 years).
The following values characterised the group
with AMI: a mean time from the onset of chest pain
of 5.6 ± 1 h; a mean value of the highest MB level
of 2329.7 ± 55.8 UI/l; mean values of the highest
CKMB level of 452 ± 16.8 IU/l; maximal ST eleva-
tion of 5.1 ± 0.7 mm.
The PCI procedures (31 patients underwent
PCI with stent implantation) were performed urgen-
tly. The results of PCI obtained in the TIMI scale
were as follows: TIMI 3 — 37 patients (88.6%);
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TIMI 2 — 5 patients (11.4%) — 2 from group S(+),
3 from group S(–). For analysis of the clinical para-
meters see Table 1.
Comparison of data such as age, body mass in-
dex (BMI), serum lipid levels, ejection fraction,
mass of the left ventricular and coronary angiogra-
phy and the results for PCI, smoking status and
concomitant diseases did not reveal any significant
differences between the study groups.
The pharmacotherapy used (aspirin, ticlopidin,
b-blockers, ACE-I, nitrates) was also comparable
in groups S(+) and S(–). The statin dose was the
only parameter that differentiated the groups exa-
mined. For analysis of the serum immune markers
see Table 2.
Mean concentrations of immune activation
markers were measured at the baseline, on the 7th,
and 30th days from the ACS.
On consecutive observation days a decrease in
PDGF concentrations was observed in group S(+),
in contrast to group S(–), in which PDGF levels in-
creased. In group S(–) a significant increase in
PDGF serum level was observed on the 30th day
from the ACS in comparison to the baseline value
(p = 0.017). The analysis of serum PDGF levels on
the 7th and 30th days of observation showed signifi-
cant differences. The mean PDGF concentrations
on the 7th and 30th days were significantly lower in
group S(+) than those observed in group S(–)
(p = 0.037, p = 0.016, respectively).
The analyses of TNF-a and sTNFR 1 concen-
trations revealed their highest levels in the period
of the ACS event in both study groups, becoming
lower over the observation period. The main diffe-
rences were found in group S(–), in which TNF-a
and sTNFR levels were significantly lower on the
7th day of observation than at the baseline. On the
30th day of observation there were no significant
differences, while TNF-a concentrations showed
a large individual variation. In group S(+) the mean
serum sTNFR 2 concentration was significantly
lower on the 30th day of therapy in comparison with
the baseline levels.
Mean TNF alpha and sTNFR 1 and 2 concen-
trations were comparable between the study gro-
ups.
There were no differences between mean IL-2
and IL-10 serum levels either in the results obta-
ined from a comparison of the study groups or in
the findings of consecutive days of observation.
Discussion
The literature data indicate long-lasting immu-
ne activation following the ACS [8, 9]. The above
analysis confirms these observations. Relatively
high serum concentrations of TNF-a, sTNFR 1, as
well as IL-2 and IL-10 have been revealed after the
ACS. It was clear that the high-dose statin  admini-
stration did not significantly modify the serum con-
centrations of 1) TNF-a — a cytokine of crucial ple-
iotropic pro-inflammatory influence, 2) TNF recep-
tors — reciprocally modifying the serum TNF
activity and 3) interleukins — neither the pro-in-
flammatory IL-2, nor the anti-inflammatory IL-10.
The analysis of the dynamics of the change in levels
of PDGF (platelet derived growth factor — a factor
produced by the endothelium and thrombocytes,
which takes part in the activation of the inflamma-
tory and aggregation/coagulation processes), howe-
ver, proved remarkable. The serum concentration
of PDGF in group S(+), originally even slightly
Table 1. Clinical characteristics of the examined
patients: the inclusion data
Group S(+) Group S(–)
N = 22  N = 22
MI 15 (68.2%) 17 (77.3%)
UA 7 (31.8%) 5 (22.7%)
Age (years) 49.4±10.5 54.3±10.5
BMI [kg/m2] 27.6±4.0 26.6±5.2
TC [mg/dl] 231.6±67.4 227.1±54.0
HDL-cholesterol 47.4±2.5 49.4±1.3
[mg/dl]
LDL-cholesterol 140.6±57.4 140.9±40.9
[mg/dl]
TG [mg/dl 188.3±121.9 153.6±70.6
LVMI [g/m2] 141.4±39.0 159.1±42.7
EF (%) 49.0±6.7 45.0±8.2
Motion score index 1.349±0.24 1.526±0.39
Coronary
angiography:
1-vessel CAD 8 (36.4%) 7 (31.8%)
2-vessel CAD 2 (9.1%) 4 (18.2%)
3-vessel CAD 12 (54.5%) 11 (50.0%)
Smoking status:
active smoker 11 (50.0%) 12 (54.5%)
ex-smoker 4 (18.2%) 4 (18.2%)
never smoked 7 (31.8%) 5 (22.7%)
Concomitant
diseases:
SH 11 (50.0%) 13 (59.1%)
DM 3 (13.6%) 5 (22.7%)
There were no significant differences between groups in all tested
parameters, MI — myocardial infarction, UA — unstable angina,
CAD — coronary artery disease, SH — systemic hypertension,
DM — diabetes mellitus TG — triglycerides, TC — total cholesterol,
BMI — body mass index, LVMI — left ventricular mass index,
EF — ejection fraction
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higher than in group S(–), decreased gradually.
A statistically significant difference was shown on the
7th day of hospitalisation, and this had increased by
day 30. In group S(–) the serum concentrations of
PDGF, higher than on admission, remained unaf-
fected on day 30. Limited data on a similar PDGF-
-release inhibiting influence of simvastatin has also
been found by other authors [10].
The significance of our results should be reflec-
ted upon in view of the available data on PDGF. The
PDGF influence on atherosclerosis development has
not been unambiguously determined. Some authors
suggest that it has a cardioprotective effect. Firstly,
PDGF is supposed to stimulate the angiogenesis in
the post-infarct myocardium [12, 13]. This effect ho-
wever, declines with age [12, 13]. In rodents PDGF
encourages the formation of angiogenesis stimulators
(angiopoietin, vessel-derived growth factor VDGF) in
young specimens, without having this effect on adults
[14]. In experimental in vitro models endothelium
cells intensify the release of PDGF in the presence
of cardiomyocytes [15] and PDGF alone enhances
stem cell differentiation into cardiomyocytes [16].
Nevertheless, the data on a positive correlation
between worse outcomes of invasive procedures in
coronary artery disease and a higher expression of
inflammatory markers, including PDGF, prevails.
The elevated serum concentration of PDGF, while
inducing the migration and proliferation of smooth
muscle cells and hyperplasia of the intima, particu-
larly in concurrence with lowered fibrinolytic
activity of the serum, is considered a major risk fac-
tor for restenosis [17]. The use of a number of me-
thods to lower PDGF activity correlates with a si-
gnificant reduction in restenosis occurrence after
percutaneous angioplasty and stenting. Those de-
scribed in the literature, mostly in animal models,
include: 1) the use of a specific inhibitor of the
PDGF-receptor tyrosine kinase, which restrains the
proliferation and migration of SMCs [18]; 2) deco-
rin — a proteoglycan-binding PDGF; 3) PDGF-spe-
cific A-chimeric DNA-RNA ribozymes hindering
post-angioplasty intima proliferation with simulta-
neously applied PDGF A and B antibodies to indu-
ce the atrophy of hyperplastic intima [19, 20].
In one of the randomised clinical trials a PDGF
antagonist, trapidil, with ticlopidine has proven as
effective in preventing restenosis after stenting as
acetylosalicic acid with ticlopidine [21].
We are not aware of the remote effects of inva-
sive treatment in our group. The administration of
high-dose simvastatin, while efficiently decreasing
the serum concentration of PDGF, may enhance the
above-described beneficial effect of PDGF inhibition
after coronary angioplasty. The lowering of PDGF
serum concentration may influence both restenosis
occurrence and early intra-stent thrombosis.
Conclusions
High-dose simvastatin, administered over
a period of one month following an ACS, has
Table 2. Mean serum concentrations of immune activation markers in patients with acute coronary
syndrome: consecutive results
Group S (+), High dose Group S (–), Low dose
PDGF [pg/ml] 0) 6202 ± 2450 0) 5884 ± 1185*
7) 6111 ± 1834$ 7) 7292 ± 1952
30) 5735 ± 1089$ 30) 7034 ± 2008
TNF-a [pg/ml] 0) 22.0 ± 3.1 0) 22.0 ± 3.1#
7) 18.2 ± 8.8   7) 15.9 ± 7.4
30) 18.6 ± 19.2 (Median: 12.5) 30) 26.3 ± 34.6 (Median: 14.2)
sTNFR 1 [pg/ml] 0) 1715 ± 546 0) 1664 ± 394#
7) 1613 ± 588 7) 1177 ± 391
30) 1493 ± 590 30) 1445 ± 636
sTNFR 2 [pg/ml] 0) 2103 ± 607* 0) 2063 ± 634
7) 1852 ± 380 7) 2082 ± 651
30) 1721 ± 688 30) 2064 ± 690
IL-10 [pg/ml] 0) 19.0 ± 3.6 0) 19.3 ± 4.9
7) 18.5 ± 4.6 7) 17.8 ± 2.9
30) 17.1 ± 3.2 30) 16.1 ± 5.5
IL-2 [pg/ml] 0) 89.7 ± 12.7 0) 86.0 ± 28.4
7) 88.8 ± 10.6 7) 82.9 ± 25.2
30) 95.9 ± 36.7 30) 81.6 ± 37.3
0) at the baseline; 7) on the 7th day; 30) on the 30th day from the enrolment; *p < 0.05 vs. result observed on the 30th day; #p < 0.01 vs. result observed
on the 7th day; $p < 0.05 vs. group S(–)
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proven to significantly decrease PDGF serum con-
centration, while having no remarkable impact on
the concentration of other well-established immune
activation markers.
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